Point72 DIFC Ltd Boosts Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Point72 DIFC Ltd boosted its stake in MiMedx Group, Inc. (NASDAQ:MDXG) by 127.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,626 shares of the company’s stock after purchasing an additional 4,275 shares during the quarter. Point72 DIFC Ltd’s holdings in MiMedx Group were worth $45,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Isthmus Partners LLC lifted its position in shares of MiMedx Group by 30.4% in the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after buying an additional 91,714 shares in the last quarter. Blue Trust Inc. purchased a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $30,000. Point72 Asset Management L.P. purchased a new stake in shares of MiMedx Group during the 2nd quarter worth approximately $40,000. Entropy Technologies LP bought a new position in shares of MiMedx Group during the 3rd quarter valued at approximately $64,000. Finally, Quest Partners LLC purchased a new position in shares of MiMedx Group in the second quarter valued at $81,000. Institutional investors own 79.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, MiMedx Group currently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Down 1.1 %

Shares of MDXG opened at $9.57 on Tuesday. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The business has a fifty day moving average of $7.28 and a 200 day moving average of $6.95. The company has a market cap of $1.41 billion, a PE ratio of 17.40 and a beta of 1.98. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $9.73.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.